

Welcome to the National Association of County and City Health Officials' Webinar on PrEP and Local Health Departments

There are two options for accessing the audio portion of this webinar: (1) Using your computer speakers (2) Dialing-in to this conference line – number: 866-740-1260; passcode: 5650851

Please note that to verbally ask a question or make a comment, you **MUST** dial-in to the conference line. If you are accessing audio via your computer speakers, you will only be able to submit questions and comments via the chat box.



PrEP and Local Health Departments: Module 1 Webinar

PRESENTED BY:

MARK THRUN, MD ASSOCIATE PROFESSOR, UNIVERSITY OF COLORADO, DIVISION OF INFECTIOUS DISEASES DIRECTOR, HIV/STD PREVENTION AND CONTROL, DENVER PUBLIC HEALTH DIRECTOR, DENVER PREVENTION TRAINING CENTER

Module 1 Overview

Webcast 1: PrEP for HIV Prevention: An Introduction

Webcast 2: Beyond the Basics: The Science of PrEP

Webcast 3: US Public Health Service Clinical Practice Guidelines for PrEP

PrEP: What are we talking about?

- A new HIV prevention option that utilizes antiretroviral HIV medications to prevent HIV infection *before* exposure to HIV
- Involves taking daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC)
 - Combination pill (brand name Truvada)
 - Approved by the U.S. Food and Drug Administration for use as HIV treatment in 2004
 - Approved for use as PrEP in July 2012

A Double-Helix HIV Prevention		Outreach and reengagement		
and Care Cor	and Care Continuum			
	Access attitudes haliste	Peer support/navigation		
Assess attitudes, beliefs, behaviors, education, and problem-solving skills	Mental health and drug-use counseling			
Linkage case management, ACA navigation, red-carpet entry programs	Screen for mental health issues, drug use, domestic violence, trauma	Case management and linkage to housing and other ancillary services	+ Adherence support	
Linkage to HIV-inclusive	Screen for risk factors and barriers	Retention in care and services	Prescribe HIV treatment	Undetectable viral load
primary care	TIVE			
HIV-POSI HIV-NEG Linkage to	TIVE	Retention in care and services	Continued risk reduction, PrEP, PEP	Remain HIV-negative
HIV-POSI HIV-NEG Linkage to primary care	TIVE ATIVE Screen for risk factors	Retention in care	1 March 1997 March 2017 March 2017	Remain HIV-negative
HIV-POSI HIV-NEG Linkage to primary care HIV risk screenings, linkage case management for high-risk	TIVE ATIVE Screen for risk factors and barriers Screen for STIs, mental health issues, drug use, domestic violence, trauma Assess attitudes, beliefs, behaviors, education, and	Retention in care and services Case management and linkage to housing and	PrEP, PEP + Regular HIV testing and reeval	Remain HIV-negative
HIV-POSI HIV-NEG Linkage to primary care HIV risk screenings, linkage case management for high-risk	TIVE ATIVE Screen for risk factors and barriers Screen for STIs, mental health issues, drug use, domestic violence, trauma Assess attitudes, beliefs,	Retention in care and services Case management and linkage to housing and other ancillary services Mental health and	PrEP, PEP + Regular HIV testing and reeval	Remain HIV-negative
HIV-POSI HIV-NEG Linkage to primary care HIV risk screenings, linkage case management for high-risk	TIVE ATIVE Screen for risk factors and barriers Screen for STIs, mental health issues, drug use, domestic violence, trauma Assess attitudes, beliefs, behaviors, education, and	Retention in care and services Case management and linkage to housing and other ancillary services Mental health and drug-use counseling	PrEP, PEP + Regular HIV testing and reeval	Remain HIV-negative

http://www.treatmentactiongroup.org/tagline/2014/spring/forgotten-negatives-limits-treatment-prevention

The Science Behind PrEP

Evolution of HIV therapies related to HIV prevention:


- Highly active antiretroviral therapy (HAART)
- Prevention of mother-to-child transmission (PMTCT)
- Post-exposure prophylaxis (PEP)
- Treatment as prevention (TasP)
- Pre-exposure prophylaxis (PrEP)

The Science of PrEP


PrEP clinical trials show efficacy of 44-73%, with greater levels of efficacy (reaching 92%) among patients who took the pill consistently.

- iPrEx Study: PrEP in MSM
- TDF2: Heterosexual PrEP Study
- Partners PrEP Study: Heterosexual Serodiscordant Couples
- Bangkok Tenofovir Study: PrEP in Injection Drug Users

Increased Adherence Associated with Increased Efficacy



Prevention Science Overview: Biomedical Intervention Efficacy



Key Messages of the Guidelines

US Public Health Service

PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES - 2014

A CLINICAL PRACTICE GUIDELINE



Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2014 Clinical Practice Guideline Page 1 of 67

Summary of Guidance for PrEP Use					
	Men Who Have Sex With Men	Heterosexual Women and Men	Injection Drug Users		
Detecting substantial risk of acquiring HIV infection:	 Sexual partner with HIV Recent bacterial STD High number of sex partners History of inconsistent or no condom use Commercial sex work 	 Sexual partner with HIV Recent bacterial STD High number of sex partners History of inconsistent or no condom use Commercial sex work Lives in high-prevalence area or network 	 HIV-positive injecting partner Sharing injection equipment Recent drug treatment (but currently injecting) 		
Clinically eligible:	 Documented negative HIV test before prescribing PrEP No signs/symptoms of acute HIV infection Normal renal function, no contraindicated medications Documented hepatitis B virus infection and vaccination status 				
Prescription	Daily, continuing, oral doeses of TDF/FTC (Truvada), ≤90 day supply				
Other services:	 Follow-up visits at least every 3 months to provide: HIV test, medication adherence counseling, behavioral risk reduction support, side effect assessment, STD symptom assessment At 3 months and every 6 months after, assess renal function Every 6 months test for bacterial STDs 				
	 Do oral/rectal STD testing 	 Assess pregnancy intent Pregnancy test every 3 months 	 Access to clean needles/ syringes and drug treatment services 		

Source: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States -2014: a clinical practice guideline.

Clinical Provider's Supplement

US PUBLIC HEALTH SERVICE

PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES – 2014 CLINICAL PROVIDERS' SUPPLEMENT



Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2014 Clinical Providers' Supplement Page 1 of 43

Local Health Departments and PrEP

What can local health departments do?

- Develop community profiles for HIV prevention planning
- Create resource inventories
- Educate at-risk community members, healthcare providers, and other HIV prevention partners
- Conduct risk assessments and make referrals for PrEP
- Support PrEP delivery (e.g. HIV and STI screening, adherence and behavioral risk counseling support)
- Deliver PrEP via health department clinics
- Evaluate and monitor HIV incidence and key PrEP performance measures

Public Health and PrEP

Local public health (PH) serves an ideal role as a connector between many parts of a broader network.



Question, Answer, and Discussion

Instructions for Asking a Question or Making a Comment

- Submit your question or comment via the chat box.
- If you are dialed-in via the conference line and would like to ask a question or make a comment verbally:
 - Raise your hand by clicking this button at the top of your screen.



- We will call on you to speak and instruct you to enter *7 to unmute your line.
- After you are done speaking, mute your line by pressing the mute button on your phone or entering *6 and click on the raise hand button to lower your hand.

NACCHO's Educational Series on PrEP and Local Health Departments

Module 1

PrEP for HIV Prevention: An Introduction

Beyond the Basics: The Science of PrEP

US Public Health Service Clinical Practice Guidelines for PrEP

Module 2

Who Might Benefit from PrEP: Population-level Risk Assessments Who Might Benefit from PrEP: Individual-level Risk Assessments

Module 3

Increasing PrEP Awareness and Knowledge in Your Jurisdiction Incorporating PrEP into Comprehensive HIV Prevention Programs

NACCHO's educational series about PrEP was supported by funding from Gilead Sciences, Inc.

NACCHO's Educational Series on PrEP and Local Health Departments

Module 2

Webcast release: Monday, November 3

Live webinar: Friday, November 21 from 1:00-2:00 PM EDT

Module 3

Webcast release: Monday, December 1 Live webinar: Tuesday, December 16 from 1:00-2:00 PM EDT